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Abstract
Background: Mannan-binding lectin (MBL) and ficolin-3 are initiators of the lectin pathway that is important 
for clearance of pathogens and apoptotic cells through complement activation. MBL deficiency (MBLD) has 
been associated with infectious complications but its clinical relevance in adults is unclear. Definition of MBLD is 
commonly linked to its low serum levels, but is mainly due to functional polymorphisms in the MBL2 gene leading 
to dysfunctional MBL forms. Homozygotes for dysfunctional alleles (O/O) have the lowest serum levels (<50 ng/ml) 
with a defect in opsonisation and complement activation. Ficolin-3 deficiency due to homozygosity of a frameshift 
mutation (1637delC) in the FCN3 gene was recently shown to be associated with pyogenic infections mainly in the 
lungs.
Objective: The aim of the study was to thoroughly evaluate the clinical findings of previously defined MBL 
deficient cohort in relation to their MBL2 and FCN3 genotypes.
Methods: A total of 120 adult individuals previously defined as MBL deficient (≤500 ng/ml) were genotyped for 
variants in the MBL2 gene and for the 1637delC allele in the FCN3 gene. They answered detailed questionnaire 
focused on pulmonary and gastrointestinal infections. For comparison, 63 adult individuals were randomly selected 
from the general population and served as control subjects. 
Results: In the MBLD cohort the prevalence of genotypes A/A, A/O and O/O was 14.2%, 71.2%, and 14.2%, 
respectively. Thus, 85% carried the dysfunctional allele O. The MBLD cohort was significantly more prone to a variety 
of recurrent and severe infections than the control cohort. O/O individuals were more susceptible to oesophagitis 
and gastritis and had undergone gastroscopy significantly more often than A/A an A/O. Prevalence of heterozygosity 
(C/-) for the 1637delC allele was 4.2%.
Conclusion: MBL deficient individuals suffer from recurrent and severe forms of infections. The O allele might 
predispose to gastrointestinal diseases.
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Introduction
Complement activation is a first-line innate defence against invading 
pathogens. Activation of complements via the lectin pathway (LP) is 
mediated by five separate soluble serum pattern recognition proteins 
(PRP). These are mannan-binding lectin (MBL), collectin- 11 (CL-11), 
ficolin-1 (M-ficolin), ficolin-2 (L-ficolin) and ficolin-3 (H-ficolin) [1-
5]. The LP-PRPs circulate in serum complexed with specific proteases 
named MASPs (MBL associated serine proteases; MASP-1, MASP-2 
and MASP-3), and upon binding to pathogen associated sugar patterns 
the MASPs become activated and initiate the complement cascade 
leading to membranolytic attack and opsonophagocytosis [6].
The physiological role of MBL has been well studied whereas the role 
of ficolins and CL-11 is less well investigated. MBL has a significant role 
in a number of pathogenetic and homeostatic processes. It binds and 
eliminates (through complement activation) various microorganisms 
and altered self-components, including dying host cells (apoptotic/
necrotic), circulating immune complexes (CICs) and immunoglobulins 
(agactosylated IgG and certain forms of IgM and IgA) [7-10]. The 
MBL molecule itself can act as a TLR-2/6 co-receptor within the cell 
and direct intracellular signalling, thus, mediating functions outside 
complement activation [11]. Additionally, MBL modulates pro-
inflammatory cytokine production and clearance of endotoxins via 
Kupffer cells [12,13].
The concentration of MBL in serum can vary 10,000-fold between 
individuals and this can be explained by combinations of single nuclear 
polymorphisms (SNPs) in exon 1 and in the promoter region of the 
MBL2 gene [14]. The SNPs in exon 1 have been named variant allele 
B,C and D (collectively called O) whereas the normal allele is referred 
to as A [14]. Individuals carrying the O allele have dysfunctional MBL 
forms unable to bind their ligands [15-17]. SNPs at positions -50 (H/L) 
and -221 (X/Y) in the MBL2 promoter and at position +4 (P/Q) in the 
5′-untranslated portion of exon 1 are associated with different MBL 
levels [18-20]. The X variant has the strongest down-regulating effect. 
Genotypes XA/O and O/O are generally referred to as MBL deficiency 
genotypes [21]. Approximately 60% of Caucasians have been found to 
be wild-type (A/A), 36% heterozygous for the O allele (A/O) and 4% 
homozygous (O/O) [14].
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MBL deficiency (MBLD) is now classified as primary 
immunodeficiency (PID) by the International Union of Immunological 
Societies Expert Committee on Primary Immunodeficencies [22]. MBL 
cutoff serum value has been defined as ≤ 500 ng/ml in a large cohort 
(N=1642) from four separate studies and has been suggested to be used 
in studies of MBL disease associations [21].
MBL-MASPs mediated defence is innate and therefore believed 
to be critical when the adaptive immune response is either immature 
and/or compromised [23]. Numerous clinical studies have linked 
MBLD with increased susceptibility to a variety of infectious diseases 
[23-28]. In addition, studies indicate that MBLD can aggravate certain 
autoimmune disorders, such as rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE) [25,29-32]. 
Ficolin-3 is the most abundant of the five LP-PRPs in serum (20 
µg/ml) [33] and the FCN3 gene is the most highly expressed gene 
in the liver and lungs among the five LP-PRPs [34]. Three cases of 
total ficolin-3 deficiency due to the 1637delC mutation have recently 
been reported [35-37]. One case was an adult with recurrent severe 
pulmonary infections, another case a neonate with necrotizing 
enterocolitis (NEC) and the third case was a premature newborn with 
Streptococcus agalactiae infections. The clinical relevance of having low 
levels or deficiency of both MBL and ficolin-3 is unknown and the role 
of ficolin-3 is still unclear. Ficolin-3 deficiency is classified as PID by the 
International Union of Immunological Societies Expert Committee on 
Primary Immunodeficencies [22].
To date, numerous disease specific cohorts have been screened for 
MBL deficiency [38]. However, to our knowledge, no data is available 
were the clinical phenotype of an adult MBLD cohort is compared 
to randomly selected cohort from the general population. Thus, we 
collected a relatively large population of adult Caucasians with low 
MBL levels (≤ 500 ng/ml), evaluated thoroughly each individual‘s 
clinical history in relation to randomly selected individuals regardless 
of their MBL and clinical status. In addition, we determined MBL2 
and FCN3 genotypes in the MBLD cohort and their potential disease 
predisposition.
Materials and Methods
Subjects and samples
From the diagnostic laboratory database at the department of 
immunology 228 individuals (≥ 18 years old) were found to have 
MBL levels ≤ 500 ng/ml measured between 2006-2009. A total of 205 
individuals were contacted and 163 of them agreed to participate in the 
study. Forty-three of these 163 were not able to attend the clinic within 
the timeframe settings for blood and data collection. Data was gathered 
from 120 individuals, 90 women (75%) and 30 men (25%). The age 
range was 18-76 years with mean age 44.7 years. Approximately 70% of 
the samples sent to our diagnostic laboratory are from ambulatory- or 
general practice settings in Iceland, sent for various medical reasons 
unknown to our laboratory. The study was approved by the National 
Bioethics Committee of Iceland and the Data Protection Committee 
of Iceland. Informed consent was obtained from all participants in 
the study. All participants answered detailed questionnaire focusing 
on health in general including infections. The questionnaire has been 
previously used in our earlier studies on IgA deficiency [39-42]. The 
control group consisted of 63 individuals (age 27 to 76 years) who were 
randomly selected from the Icelandic National Registry [39,40,42]. 
Serum and EDTA blood were collected from all participants. Serum was 
frozen at -80°C until used in ELISA (enzyme-linked immunosorbent 
assay) and EDTA blood was kept at -20°C until DNA was isolated. 
Genomic DNA was extracted from EDTA blood samples using 
NucleoSpin® Blood QuickPure kit (Machery-Nagel, catno: 740569.50) 
according to the manufacturer’s instructions. 
MBL2 and FCN3 genotyping 
The MBL2 variants in exon 1; Arg52Cys (D) (rs5030737), Gly54Asp 
(B) (rs1800450) and Gly57Glu (C) (rs1800451) were analysed with real-
time polymerase chain reaction (PCR) using fluorescent hybridization 
probes with subsequent melting temperature (Tm) curve analysis on a 
LightCycleTM instrument (Roche Diagnostics. Mannheim. Germany) 
as described previously [43]. To screen for the frameshift mutation 
(rs28357092, 1637delC) in the FCN3 gene we used restriction fragment 
length polymorphism PCR (RFLP-PCR) as previously described [35]. 
Briefly, a 650 bp PCR product spanning the putative mutation site is 
amplified and digested with ApaI restriction enzyme. When run on 
agarose gel the wild-type genotype (C/C) represents 2 bands (384 bp 
and 266 bp), heterozygotes (-/C) represent 3 bands (650 bp, 384 bp 
and 266 bp) and homozygotes represent undigested product (650 bp). 
Mutation analysis was confirmed with Sanger sequencing (sequencing 
service of company Microsynth AG, Switzerland). 
MBL serum levels
MBL serum levels were measured using a sandwich ELISA system 
previously described (29).
Figure 1: (A) Distribution of MBL levels in control subjects (n=63) and MBLD 
subjects (n=120). (B) Distribution of MBL levels of the MBL2 genotypes within 
the MBLD cohort.
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Statistical analysis
The two cohorts were compared with the Mann-Whitney U test 
in case of continuous variables and Kruskal-Wallis H test was applied 
when comparing the three genotype subgroubs of the MBLD cohort. 
Categorical data was compared with χ2 test or Fisher‘s exact test. The 
level of significance was set at 0.05 and the program package SPSS 11.0 
(SPSS, Inc, Chicago, Ill) was used for processing the data.
Results
MBL serum levels in the cohorts and among the MBL2 
genotypes
Distribution of MBL serum levels of the control (n=63) and 
MBLD (n=120) subjects is illustrated in Figure 1A. Mean MBL levels 
for controls and MBLD were 1564 and 175 ng/ml, respectively. The 
Figure 2: MBLD individuals (n=120) are more prone to various infections than controls (n=63). (A) Occurence of respiratory tract infections. (B) 
Occurrence of gastrointestinal infections. (C) Occurrence of mucosa, cutaneous and blood infections. (D) Occurrence of urogenital infections. 
Reported occurrence over time interval is indicated in each graph. The Y-axis represents number of individuals (as percent of n) [y: years; m: 
months].
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prevalence of the MBL2 genotypes A/A, A/O and O/O was 14.2% 
(17/120), 71.7% (86/120), and 14.2% (17/120), respectively. Thus, 85% 
of the MBLD cohort carried the dysfunctional allele O. In addition, 
17/50 (34%) of MBLD individuals with MBL levels ≤ 50 ng/ml were of 
the O/O genotype. Mean MBL levels for genotype A/A, A/O and O/O 
were 320 ng/ml (range 220-500) , 177 ng/ml (range 50-410 ng/ml) and 
50 ng/ml (no range), respectively (Figure 1B). 
Clinical manifestations of the MBLD cohort
Respiratory tract infections: The MBLD cohort reported a higher 
12-month incidence of common cold (MBLD 28.3% versus control 
7.9%, p=0.0014) (Figure 2A). In addition, otitis media, sinusitis, 
pharyngitis, tracheitis, bronchitis and pneumonia were significantly 
more often reported by the MBLD cohort the preceding 5 years 
compared to controls (Figure 2A). The difference between the two 
cohorts was highly significant (p<0.0001) in the case of sinusitis (MBLD 
64% versus control 25%), tracheitis (MBLD 37.5% versus control 9.5%) 
and pneumonia (MBLD 35% versus control 1.6%). In contrast, there 
was no statistical difference in the incidence of pleurisy betweeen the 
two cohorts (Figure 2A). Thus, as could be expected, MBLD individuals 
had significantly more often undergone tonsillectomy (MBLD 47% 
versus control 24%, p=0.003) and adenoidectomy (MBLD 24% versus 
control 8%, p=0.009). 
Gastrointestinal infections: Surveying the gastrointestinal 
symptoms profile of the two groups revealed that the occurrence of 
oesophagitis and gastritis in the preceding 5 years was high among MBL 
deficient individuals and signficantly higher than found in the control 
cohort (Figure 2B). In addition, about 8% of the MBLD individuals had 
more than five episodes of gastritis over the last two years, whereas none 
of the control cohort had (p<0.0001). Furthermore, the MBLD cohort 
had significantly more often been subjected to gastroscopy (MBLD 61% 
versus control 24%, p<0.0001). Interestingly, four individuals had been 
diagnosed with Campylobacter infections and they all belonged to the 
MBLD cohort. The two cohorts did not differ in occurence of ulcer 
(MBLD 8.5% versus control 1.6%, p=0.0642) or Salmonella infections 
(MBLD 3.3% versus control 1.6%, p=0.48957).
Mucosa, cutaneous and blood infections: The MBLD individuals 
reported a significantly higher incidence of stomatitis, conjunctivitis 
and onychia than the control group (Figure 2C). In addition, gingivits 
tended to be higher amongst MBLD individuals (MBLD 41.5% 
versus control 28.6%, p=0.0868). No difference was detected between 
the groups regarding prevalence of external otitis and bacterial 
skin infections the preceding 5 years (MBLD 12.6% versus control 
7.9%, p=0.3408 and MBLD 17.8% versus control 19.0%, p=0.8377, 
respectively). Eleven MBLD individuals reported 1-4 episodes of sepsis 
the preceding 5 years, whereas no one in the control cohort did (Figure 
2C). No difference was found between the two cohorts in the recurrence 
(≥ 5 times last 12 months) of herpes labialis (MBLD 6% versus control 
2%, p=0.840). 
Urogenital infections: About 25% (8/32) of the men in the 
MBLD cohort reported prostatitis ≥ 1 times in the 5 preceding years, 
whereas only 5.9% (2/34) of the men in the control cohort did (Figure 
2D). Episodes (1-4 times the last 12 months) of common infections 
such as cystisis, urethritis and bacterial infections of the vagina 
were significantly more frequent in the MBLD group (Figure 2D). 
The cohorts neither differed in reported frequencies of vaginal yeast 
infections nor nephritis (MBLD 47.8% versus control 37.9%, p=0.3582 
and MBLD 6.7% versus control 3.2%, p=0.3208, respectively). 
Antibiotic treatment: Antibiotic treatment during the last 12 
Figure 3: (A) Antibiotic use among the MBLD individuals (n=120) and controls (n=63). Use of antibiotics the last 12 months is shown. The X-axis 
represents the number of systemic antibiotic treatments. The Y-axis represents the number of individuals (as percent of n). (B) MBLD individuals 
are highly susceptible to recurrent and severe infections. The reported frequencies of different types of infections were classified into three classes 
(incremental infection proneness and severity from 1 to 3) [42].
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months was significantly more common in the MBLD cohort compared 
to controls (Figure 3A). In addition, the MBLD individuals needed at 
some time in their life prophylactic antibiotic therapy more often than 
the control group (MBLD 34% versus control 14%, p=0.0001).
Recurrent and severe infections: The infections were classified 
into three classes according to severity and frequency (Figure 3B). 
This classification is based on a study-specific classification system 
previously used in our studies on clinical manisfestations of selective 
IgA deficiency [42]. The infections subjected to this analysis were 
common cold, pharyngitis, sinusitis, tracheitis, bronchitis, pneumonia, 
urethritis, prostatitis and conjunctivitis. Approximately 43% of the 
MBL deficiency individuals suffered from recurrent and severe 
episodes of infections (class 3), whereas only 16% of the control group 
did (p=0.0003) (Figure 3B). 
MBL2 and FCN3 genotypes and clinical findings
Recurrent common cold was relatively more often reported by the 
O/O genotype subgroup than in the A/A genotype subgroup (Figure 4A). 
However, no association was detected between genotype and various 
upper and lower respiratory infections (Figure 4A). Interestingly, 
among the individuals in the MBLD cohort that reported pleurisy, two 
were O/O (2/17), one A/O (1/86) and no one was A/A (0/17) (Figure 
4A). The O/O genotypes reported 4-7 episodes of pleurisy the last two 
years whereas the A/O genotype reported 1-2 times the last two years. 
Significantly higher occurrence of gastritis was found among 
individuals with the O/O genotype and they also tended to have higher 
frequency of oesophagitis than A/O and A/A and genotypes (Figure 
4B). In the case of gastritis, the effect of the O allele tends to be gene 
doze dependent. In addition, O/O genotypes had significantly more 
often been subjected to gastroscopy than A/O and A/A genotypes 
(Figure 4B). However, no association was detected between genotypes 
and Salmonella/Campylobacter infections or ulcer (data not shown). 
The O/O subgroup tended to have higher frequency (1-4x per 
year) of labial herpes (41.2% (O/O), 23.8% (A/O) and 11.8% (A/A), 
p=0.1337). In contrast, gingivitis appeared to be rare amongst O/O 
individuals (17.6% (O/O), 44.7% (A/O) and 50% (A/A), p=0.0917). 
Stomatitis, conjunctivitiis, cutaneous infections, urogenital infections 
and sepsis were not associated with genotype (data not shown). 
Five individuals in the MBLD cohort (4.2%) were heterozygous (C/-) 
for the 1637delC allele in the FCN3 gene. This is higher heterozygote 
frequency than we have observed previously in 500 Icelandic blood 
donors (2%) (unpublished data). The MBL serum levels of the C/- 
individuals ranged from 350 to 500 ng/ml and the MBL2 genotypes 
were all A/O (three A/B, one A/C and one A/D). The MBLD individuals 
heterozygous for the 1637delC allele were not more susceptible to 
infections then the wild-type inidividuals (C/C), regardless of MBL2 
genotype.
Discussion
In this case-control study, we found that adult MBL deficient 
Figure 4: O/O genotype is a potential risk factor for gastritis. (A) Comparison of occurrence of respiratory tract infections between MBL2 genotypes 
within the MBLD cohort (n=120). (B) Comparison of occurrence of gastrointestinal symptoms between MBL2 genotypes. Reported occurrence over 
time interval is indicated in each graph. The Y-axis represents the number of individuals in each genotype group of the MBLD cohort (as percent 
of n) [y: years; m: months].
Citation: Bjarnadottir H, Thorsteinsdottir V, Jorgensen GH, Arnardottir M, Ludviksson BR (2014) Mannan-Binding Lectin (MBL) Deficient Individuals 
with the O/O Genotype are Highly Susceptible to Gastrointestinal Diseases. J Clin Cell Immunol 5: 182. doi:10.4172/2155-9899.1000182
Page 6 of 8
Volume 5 • Issue 1 • 1000182
J Clin Cell Immunol
ISSN: 2155-9899 JCCI, an open access journal 
individuals have increased proneness to various respiratorial, 
gastrointestinal, urogenital, muccosal, skin and blood infections 
compared to a randomly selected control group. In addition, we found 
that the infections were recurrent and severe in the MBLD cohort. 
Furthermore, we showed that MBLD individuals with the O/O genotype 
were significantly more likely to suffer from oesophagitis and gastritis 
as well having undergone gastroscopy than MBLD individuals with the 
A/O and A/A genotypes. 
Our results on high occurrence of respiratory tract infections 
in adult MBL deficient individuals support previous findings [44]. 
However, our MBLD cohort was more frequently diagnosed with 
sinusitis than previously reported [44]. The high insidence of 
tonsillectomy and adenoidectomy among MBL deficient individuals 
has also been previously observed among MBLD individuals [45]. In 
addition, we found that tonsillectomy tended to be linked to the O 
allele which also supports previous results [45]. It has been shown that 
pneumonia caused by Streptococcus pneumoniae is linked to the O allele 
and low MBL levels increases the death due to pneumococcal infection 
[21,46]. Since our questionnarie was retrospective it is not possible to 
identify the underlying cause of pneumonia of our study cohort.
Previous studies have also reported significantly increased 
frequency of severe MBL deficiency (MBL levels ≤ 50 ng/ml) in adult 
patients with a history of recurrent/and or severe infections, including 
pneumonia and bronchitis [44]. In that study, it was ascertained that the 
patients neither had concomitant immunodeficiencies nor had received 
immunosuppressive therapy [44]. Our results (Figure 3B) support their 
findings, however we can not rule out that MBL deficiency was the 
only cause to increased infection susceptibility because concomitant 
immunodeficiencies were not investigated in our study.
Interestingly, 9.3% of the MBL deficient individuals have had more 
than one episode of sepsis during the last 5 years, whereas none of the 
control group had (p=0.013). These results are in concordance with 
previous reports which indicate that high serum MBL levels may be 
protective against sepsis [47,48]. The MBL2 geneotypes did not differ 
with respect to occurrence of sepsis in our study which contrasts other 
findings suggesting that the O allele predisposes to sepsis [49,50].
What is perhaps the most outstanding finding in our study is 
the significant association we found between O/O genotypes and 
gastrointestinal inflammatory symptoms. Supporting this association is 
the observation that O/O genotypes had significantly more often been 
subjected to gastroscopy (Figure 4B). Previous studies have shown 
that the O allele is associated with a risk of developing more severe 
gastric mucosal atrophy and intestinal metaplasia in Helicobacter pylori 
infected individuals [51]. Other studies have shown that the O allele 
is not linked to chronic gastritis, dyspepsia, duodenal ulcer, ulcerative 
colitis (UC) and/or Chron‘s disease [52-56]. The cause behind the high 
gastrointestinal inflammatory symptoms among O/O genotypes in our 
study and the role of MBL in upper gastrointestinal immunity remains 
unclear. Our observation awaits further studies.
The immune system in immunocompetent individuals has various 
compensatory mechanisms to counteract deficiency in other pathways. 
Whether the LP-PRPs can compensate for each other is unknown. We 
screened for the ficolin-3 deficiency allele (1637delC) in the MBLD 
cohort. None of the five heterozygotes we found were O/O and their 
MBL levels were all above 350 ng/ml. Although one can not conclude 
from data of such a small group of individuals, one might postulate 
that carrying both the O/O genotype and the C/- or -/- genotype could 
be more relevant for survival and susceptibility to infectious diseases. 
Elevated levels of ficolin-2 has previously been reported in O/O patients 
[57]. An observation that suggests that ficolin-2 might be compensating 
for MBL deficiency. This may also apply for ficolin-3. Ficolin-2 and 
ficolin-3 are both expressed in liver, have high structure homology, share 
ligand binding affinity, circulate in serum and both initiate the LP [58]. 
Ficolins may substitute for MBL deficiency and this may explain why 
the frequency of the O/O genotype is relatively high in Caucasians (4%) 
and why a subset of O/O individuals are healthy [24,59]. Our results 
warrant further studies involving screening for both deficiency alleles 
(i.e. O and 1637delC) in larger and different cohorts and investigate the 
advantages and/or disadvantages for the individual.
The results of our study indicate that more clinical attention should 
be made to adult patients with MBL deficiency. The MBLD cohort 
was highly susceptible to infections, therefore the MBL serum levels 
of patients with recurrent and severe infections should be routinely 
determined. The O allele was only associated with oesophagitis, gastritis 
and gastroscopy but not with the various respiratorial, urogenital, 
skin, mucosal and blood infections in the MBLD cohort. Thus, 
more attention needs to be made towards MBL2 genotyping patients 
with gastrointestinal complications. Genotyping of a larger study 
cohort which includes patients with gastrointestinal inflammation 
symptoms is warranted to better understand the significance of MBL in 
gastrointestinal immunity and/or homeostasis.
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